Lynnet Koh MBA, CEO, Chairman
Lynnet has successfully led the research, development, manufacturing of Targazyme’s immuno-oncology drugs from idea stage to completion of phase 2 clinical trials where Targazyme’s drug is shown to improve cancer patient survival and quality of life as well as positioning the company for Phase 3 readiness/multiple shots on goal. Key milestones and awards received: FDA Phase 3 Special Protocol Assessment, multiple FDA Orphan Drug Designations, worldwide patents. Major validation received: $40MM+ of prestigious peer-reviewed medical awards for the advancement of the fucosyltransferase recombinant human enzyme technology with leading clinical collaborators, publications in Blood, Clinical Cancer Research and Nature, collaborations with Astellas, Kyowa Hakko Kirin, Vidacord, Poseida Therapeutics, Allogene and leading research centers such as MD Anderson Cancer Center and OMRF.
Lynnet has a passion for, and a proven track record with leading transformative technology innovations from idea stage through design, development, manufacturing, global launch and achievement of market-leading commercial revenues across multiple industries. They include: Targazyme’s novel enzymes with their potential for improving the efficacy, safety and cost of care for cell therapy, the world’s first generation caller ID product (AT&T Bell Labs) which enables people to see the caller’s name and number, first-generation wireless systems (AT&T Bell Labs) which enables people to be reached anytime, anyplace, anywhere; first-generation voice/video/data infrastructure products (Cisco Systems) which enables people to have voice/video communications over the internet. Several of the products that she managed commanded #1 market share in their sectors and won best in class awards. Companies, where she held key general management/program leadership roles, include Cisco Systems, AT&T, Qualcomm.
Lynnet received an MBA with honors from the Massachusetts Institute of Technology and Bachelor of Science in Finance with honors in 2 years from Boston University.
Tom Bliss, Acting CFO & Board Member
Tom is concurrently the CBO of Taiwan Liposome. Tom was previously the former CEO of Genisphere, VP of Business Development at Baxter, Head of the Business Development Group at Amgen where he directed all M&A and Licensing operations and Johnson & Johnson where he was in charge of licensing projects. He was at Donaldson, Lufkin & Jenrette New York as Vice President, Biotech Corporate Finance where he led multiple life sciences debt/equity financings, IPO and acquisition advisory projects. Tom received his MBA from the Wharton School of Management, University of Pennsylvania and Bachelor of Arts Degree from Dartmouth College.
Mark Frolich, MD
Dr. Frohlich is an experienced medical oncologist and biotechnology executive with expertise in drug development of cell & gene therapies, oncology, and immunology. Dr. Frohlich has been involved in the development of immunotherapies for cancer for 20 years. He was most recently Executive VP of Portfolio Strategy at Juno Therapeutics prior to its acquisition by Celgene. He previously served as Executive VP of R&D and Chief Medical Officer of Dendreon Corporation, where he led the clinical team responsible for the approval of the first cellular immunotherapy in the US and Europe (Provenge®). Dr. Frohlich is a graduate of Yale College with a BS in Economics and Electrical Engineering summa cum laude, and Harvard Medical School with a Doctor of Medicine degree. He was Chief Medical Resident and completed an internal medicine residency and subsequently completed the oncology fellowship program, both at UCSF.
Gary Frashier, PhD
Mr. Frashier served as Chief Executive Officer and Chairman of OSI Pharmaceuticals, and it was during his tenure at OSI that the leading genetic-based cancer drug, “Tarceva” was discovered and developed thru initial human Proof of Concept clinical trials. Tarceva is now sold by Roche and Genentech and has annual sales of over $1.7 billion with continuing expansion into new cancer areas. Astellas Pharma acquired OSI in 2010 for $4 billion. Mr. Frashier has raised over $250 million from a combination of equity financings and other sources, has organized many collaborations and joint programs with major pharmaceutical companies and has served as a founder of several life science companies. Prior to OSI, Mr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; and CEO of Genex Corporation, a protein engineering company. He has participated as a founder in organizing several biotechnology companies, including Merrimack Pharmaceuticals, Inc.; Eutropics, Inc.; Targazyme and Apex BioVentures Acquisition Corporation. He currently serves on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ), ViroXis Corporation, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis Corporation and StemBioSys. He is a Strategic Partner in SV Life Sciences LP, a major venture capital company. He has served on numerous other private and public life science company Boards, including Maxim Pharmaceuticals, Tekmira Pharmaceuticals (Canada), Apex BioVentures Acquisition Corporation, Tanox, Inc., Cytoclonal Pharmaceuticals, Exegenics Pharmaceuticals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals. Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a “Distinguished Engineer Graduate,” and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an “Alfred P. Sloan Fellow.” He is a registered Professional Engineer in Chemical Engineering in Texas.
Alan Lewis, Ph.D.
Dr. Lewis is currently CEO and Director of Medistem, Inc. He was recently President, CEO and Chairman of Ambit BioSciences, and previously President and CEO of the Juvenile Diabetes Research Foundation and President, CEO and Director of Novocell, Inc. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases, after which he served as President of the Signal Research Division at Celgene. Before joining Signal, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin Pharmaceutical, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.
Art Benvenuto, PhD
Art is the Founding Business Advisory Board member of Targazyme. He is currently the Chairman and Chief Executive Officer of Micell Technologies. Prior to being named to his current role, Art served as Chairman, Life Sciences for RA Capital Group, an advisor to venture capital firms, as well as a board member of other biotech and medical device companies. He was also an early principal and the Chairman & CEO of Advanced Tissue Sciences, Inc. (ATS), a public biotechnology firm focused on the field of tissue engineering. Prior to joining ATS, Art served as President and General Manager of Eli Lilly Canada, Inc. and was President & CEO of IVAC Corp., a medical device company previously owned by Eli Lilly (now part of Care Fusion/BD). Art also held various marketing and sales management positions within the Pharmaceutical Division of Lilly as well as within the medical device subsidiary, IVAC. He holds a B.S. in Pharmacy and an honorary Doctor of Science from St. John’s University.
Art’s previous board appointments include: Scripps Institute of Medicine and Science; The Scripps Research Institute; Scripps Memorial Hospital Foundation (where he served as President); Project HOPE, an international health and education foundation; La Jolla Cancer Foundation (now Sanford-Burnham Medical Research Institute); Board of Overseers for the University of California, San Diego; Governor’s Council on Biotechnology (California); San Diego Economic Development Corporation; City National Bank (San Diego Advisory Board); and BIOCOM (San Diego), where he was a founding board member. Art has acted as a former board member and advisor to certain other privately-held and publicly-traded biomedical companies.